Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria
Launched by GRUPO DE ALERGOLOGÍA CLÍNICA Y EXPERIMENTAL · Sep 8, 2013
Trial Information
Current as of June 26, 2025
Completed
Keywords
ClinConnect Summary
This was a randomized, double-blind, study that was conducted in six health care centers from Medellín and Bogotá (Colombia). This study was conducted in compliance with the ethical principles of the Declaration of Helsinki and with Good Clinical Practice guidelines. Written informed consent was obtained from all subjects or they parents in patients under 18 years. Ethical committee of University of Antioquia (Medellín, Colombia) approved the protocol. Considering the large number of articles that demonstrate the efficacy of antihistamines as first-line treatment in patients with urticaria,...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical diagnosis of persistent allergic urticaria.
- • Age over 12 years and at least one year with the disease
- • Informed consent filled.
- • Be resident of the metropolitan area of Medellin.
- Exclusion Criteria:
- • • Use of immunosuppressive drugs
About Grupo De Alergología Clínica Y Experimental
Grupo de Alergología Clínica y Experimental is a leading clinical research organization dedicated to advancing the understanding and treatment of allergic conditions through innovative research and rigorous clinical trials. Committed to improving patient outcomes, the group collaborates with healthcare professionals and institutions to conduct high-quality studies that assess novel therapies and interventions. With a focus on allergy-related disorders, their expertise encompasses a wide range of clinical and experimental approaches, ensuring a comprehensive evaluation of therapeutic efficacy and safety. Through their work, they aim to contribute to the development of effective solutions that enhance the quality of life for patients suffering from allergies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Medellin, Antioquia, Colombia
Patients applied
Trial Officials
Jorge Sánchez, M.D
Principal Investigator
IPS Universitaria, University of Antioquia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials